Business
Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT Webinar to include presentations by Daré management and key opinion leaders in reproductive and
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"Webinar to be held Tuesday, July 11, 2023, at 4:30 p.m. EDT Webinar to include presentations by Daré management and key opinion leaders in reproductive and sexual medicine SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a virtual Key Opinion Leader (KOL) webinar on Tuesday, July 11, 2023, at 4:30 p.m. EDT to review additional data from its exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder (FSAD). In addition to the data presentation, the webinar will include discussions on the diagnosis and treatment of FSAD, the unmet medical need among women and the market opportunity for a pharmacologic treatment for FSAD. Daré and its collaborator, Strategic Science & Technologies, LLC, a Cambridge, MA based novel topical drug delivery company, previously announced positive topline data from the study. Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will host the webinar and will be joined by: Sheryl A. Kingsberg, PhD, Division Chief of Behavioral Medicine, Department of OBGYN, University Hospitals Cleveland Medical Center, Ohio, and Past President of The International Society for the Study of Women's Sexual Health (ISSWSH), as well as Past President of The North American Menopause Society (NAMS), andJames A. Simon. M.D., CCD, NCMP, IF, FACOG, Clinical Professor, Obstetrics and Gynecology, George Washington University and President and Medical Director of IntimMedicine Specialists®, as well as Past President of each of NAMS and ISSWSH. A link to access the live webinar will be available under “Presentations, Events & Webcasts\" in the Investors section of the Company's website at http://ir.darebioscience.com. Following the conclusion of the live event, a replay will be available under “Presentations, Events & Webcasts\" in the Investors section of the Company's website at http://ir.darebioscience.com until September 1, 2023. About FSAD and Sildenafil Cream, 3.6% FSAD is a condition characterized primarily by a persistent or recurrent inability to attain or maintain sufficient genital arousal (an adequate lubrication-swelling response) during sexual activity, frequently resulting in distress or interpersonal difficulty, and, of the various types of female s...